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Abstract: Affordability of healthcare is highly limited by its skyrocketing cost. Access to screening and diagnostic medical 
equipment and medicine in developing countries is inadequate for the majority of the population. There is a tremendous 
worldwide need to detect breast cancer at its earliest stage. These needs must be balanced by the ability of countries to 
provide breast cancer screening technology to their populations. We reviewed the diagnostic accuracy, procedure cost and 
cost-effectiveness of currently available technique for breast screening and diagnosis including clinical breast examination, 
mammography, ultrasound, magnetic resonance imaging, biopsy and a new modality for cancer diagnostics termed elasticity 
imaging that has emerged in the last decade. Clinical results demonstrate that elasticity imaging even in its simplest and 
least sophisticated versions, like tactile imaging, has signiﬁ  cant diagnostic potential comparable and exceeding that of 
conventional imaging techniques. In view of many countries with limited resources, effective yet less expensive modes of 
screening must be considered worldwide. The tactile imaging is one method that has the potential to provide cost-effective 
breast cancer screening and diagnostics.
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Introduction
Affordability of healthcare is highly limited by its skyrocketing cost. Access to screening and diagnostic 
medical equipment and medicine in developing countries is inadequate for the majority of the popula-
tion. More than 70% of all cancer deaths occur in low and middle income countries, where resources 
available for diagnosis, prevention, and treatment of cancer are limited or nonexistent[1, 2]. One of 
reasons for rapid escalation of the healthcare costs is an application of new advanced techniques for 
diagnostics, treatment and prevention which often is not cost-effective. For example, Medicare’s reim-
bursement system is establishing the minimum reimbursement for mammography services as 81.86 
USD for ﬁ  lm and 131.50 USD for digital bilateral screening mammography[3] which corresponds to 
60.6% increase in the procedure cost. Despite such an increase of costs, the improvement of diagnostic 
accuracy of digital relative to ﬁ  lm mammography is not signiﬁ  cant. The overall diagnostic accuracy in 
a large-scaled clinical study was found of 0.78 ± 0.02 for digital mammography and of 0.74 ± 0.02 for 
ﬁ  lm mammography (difference 0.03; 95% conﬁ  dence interval, −0.02 to 0.08; P = 0.18)[4]. Digital 
mammography, compared with ﬁ  lm, would cost more than 300,000 USD per quality-adjusted life-year 
gained, which is not cost effective[5].
These and other similar data indicate that there is an urgent need in cost effective screening and 
diagnostic methods for breast cancer, making it affordable all around the world[6].
Current Screening and Diagnostic Methods
Current methods of breast screening and diagnosis include Breast Self-Examination (BSE), Clinical 
Breast Examination (CBE), Mammography, Ultrasound, Magnetic Resonance Imaging (MRI), and 
biopsy. Other breast screening methods which are currently in an exploratory stage include: tomosyn-
thesis, supersonic shear wave imaging, electrical impedance tomography, optical tomography, and 
several second line breast pathology diagnostic techniques such as positron emission tomography and 
scintimammography.92
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BSE
The studies of the effectiveness of BSE as a 
detection modality has shown mixed results, but 
recent data reviews have focused on the lack of 
direct beneﬁ  t in randomized clinical trials[7–9]. 
The studies found no reduction in the breast cancer 
mortality but higher rate of benign biopsy, in 
women who regularly perform BSE compared to 
women who do not regularly perform BSE [8]. 
Although the American Cancer Society no longer 
recommends that all women perform monthly BSE, 
women are recommended to be informed about the 
potential beneﬁ  ts (self-awareness) and limitations 
(false-positive rate) associated with BSE. Women 
who detect their own breast cancer usually ﬁ  nd it 
outside of a structured breast self-exam while 
bathing or getting dressed. A woman who wishes 
to perform periodic BSE should receive instruction 
from her health care provider and/or have her 
technique reviewed periodically[10].
CBE
The premise underlying CBE is utilizing a trained 
clinician to visually inspect and palpate the breast 
in order to detect abnormalities to ﬁ  nd palpable 
breast cancers at an earlier stage[11]. American 
Cancer Society guidelines recommend an annual 
CBE for age 40 and older for early detection of 
breast cancer in asymptomatic women[10]. The 
CBE may identify some cancers missed by 
mammography[12, 13] and provide an important 
screening tool among women for whom mam-
mography is not recommended or who do not 
receive recommended high-quality screening 
mammography. At the same time, CBE perfor-
mance, reports and documentation are inconsistent 
and not standardized. Health care providers report 
a lack of conﬁ  dence in their CBE skills and would 
welcome training and practical recommendations 
for optimizing performance and reporting[14].
Data from six studies examined by Barton et al. 
resulted in an overall estimate of 54.1% for CBE 
sensitivity and 94.0% for CBE speciﬁ  city[15]. 
Over 20 years ago, Haagensen [16] estimated that 
65% of 2,198 breast cancer cases, identiﬁ  ed before 
the use of screening mammography, presented as 
a breast masses detected by BSE or CBE. These 
ﬁ  ndings are comparable to the published values for 
CBE sensitivity (58.8%) and speciﬁ  city (93.4%) 
observed in the U.S. national screening program 
for 752,081 CBE reports[17]. The CBE cost 
effectiveness in cancer screening is 3.5 fold better 
than that of mammography[18]. The CBE detects 
only 34% fewer breast cancers than mammography, 
as it was demonstrated for population of 1 million 
women and the cost-effectiveness of biennial CBE 
is evaluated as 522 USD per life-year saved in India 
[18]. From this point, CBE may be a suitable option 
for countries in economic transition, where inci-
dence rates are on the increase but limited resources 
do not permit screening by mammography.
In Japan, for women aged 40–49 years, having 
the highest incidence rate of breast cancer, the 
cost-effectiveness of annual CBE per life-year was 
evaluated as 31,900 USD[69].
Mammography
Mammography provides X-ray images of the 
breasts with at least two sets of images, the medio-
lateral oblique and cranial-caudal views. A recent 
large-scale clinical study (42,760 patients in U.S.A. 
and Canada) on the diagnostic performance of 
mammography for breast-cancer screening dem-
onstrated a sensitivity of 70.0%, speciﬁ  city of 
92.0%, and diagnostic accuracy interpreted as 
AUC of 78.0%[4]. The European randomized 
mammography screening trial (23,929 patients in 
Norway) revealed a sensitivity of 77.4% and 
speciﬁ  city of 96.5% at full-ﬁ  eld digital mammog-
raphy. The median size of screening-detected 
invasive cancers was about 13.5 mm[19]. In the 
United States, despite the recommendation for an 
annual mammogram, in 2005 only 47.8% of women 
aged 40–49 years had a mammogram within the 
past year. Among the women without health insur-
ance coverage this value decreases to 24.1% [10]. 
The cost-effectiveness screening ﬁ  lm mammogra-
phy are estimated as 902–1,946 USD per year of 
life saved in India, 2,450–14,790 USD per year of 
life saved in Europe, and 28,600–47,900 USD per 
year of life saved in U.S.A.[6]. Among the limita-
tions of mammography are increased breast density, 
technical factors, e.g. areas adjacent to the chest 
wall may not be imaged[20], lack of insurance 
coverage, disagreements among primary care phy-
sicians on frequency of mammographic screening, 
variation in interpretation skills of radiologists.
The mean glandular radiation dose from 2-view 
mammography is approximately 4 to 5 mGy and 
the dosage varies among facilities and increases 
with breast density. The average cumulative 
exposure from screening during the decade will be 93
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around 60 mGy[70]. There is a strong linear trend 
of increasing risk of radiation-induced breast 
cancer with increasing radiation dose (P = 0.0001) 
[71]. A statistically signiﬁ  cant increase in the inci-
dence of breast cancer following radiation 
treatment of various benign breast diseases was 
observed[72]. Several recent studies suggesting 
that carriers of pathogenic alleles in DNA repair 
and damage recognition genes may have an 
increased risk of breast cancer following exposure 
to ionizing radiation, even at low doses[73]. Based 
on review of 117 studies related to screening mam-
mography the authors concluded that “the risk for 
death due to breast cancer from the radiation expo-
sure involved in mammography screening is small 
and is outweighed by a reduction in breast cancer 
mortality rates from early detection.”[74].
Ultrasound
Ultrasonography as an imaging tool uses sound 
waves that pass through breast tissue and are 
reﬂ  ected back characterizing tissue structure. Ultra-
sonography is typically used as a complementary 
method for the assessment of mammographically or 
clinically detected breast masses and for supplemen-
tal information on dense tissue[11]. However, there 
is limited data supporting the use of ultrasound in 
breast cancer screening as an adjunct to mammog-
raphy[21]. The conventional ultrasound is more 
often used to evaluate an area of concern on mam-
mogram. The majority of cystic masses are benign 
while solid masses need further evaluation[22]. 
Ultrasound is often confused as a screening tool by 
both patients and healthcare providers. However, 
ultrasonic screening the entire breast is not only 
labor-intensive, but operator-dependent; therefore, 
ultrasound is a difﬁ  cult tool to use if there is not an 
identiﬁ  able area of concern. Ongoing studies are 
trying to determine whether there is a population of 
women who would benefit from an ultrasonic 
screening; however, at this time, it is not the standard 
of care and whole-breast ultrasonography for 
screening has not been established as useful[23]. 
The cost associated with unilateral or bilateral ultra-
sound diagnostic procedure is 70.11 USD according 
to 2005 U.S. average Medicare reimbursements[5].
MRI
MRI utilizes magnetic ﬁ  elds to produce detailed 
cross-sectional images of the breast tissue. Image 
contrast between tissues in the breast (fat, glandular 
tissue, lesions, etc.) depends on the mobility and 
magnetic environment of the hydrogen atoms in 
water and fat that contribute to the measured signal 
that determines the brightness of tissues in the 
image. Many indications for clinical breast MRI 
are recognized, including resolving ﬁ  ndings on 
mammography and staging of breast cancer[22]. 
Overall, the results of 6 nonrandomized prospec-
tive studies in the Netherlands[24], the United 
Kingdom[25], Canada[26], Germany[27], the 
United States[28], and Italy[29] of MRI efﬁ  cacy 
in breast cancer screening for high risk women 
populations demonstrate an averaged sensitivity 
of 87.5% and speciﬁ  city of 92.8%. Only limited 
data are available on the cost effectiveness of breast 
MRI screening being combined with mammogra-
phy. The cost per quality-adjusted life year saved 
for annual MRI plus ﬁ  lm mammography, compared 
with annual ﬁ  lm mammography alone, varied by 
age and other factors to be found in the range of 
27,544–130,420 USD. The reimbursement for 
bilateral MRI diagnostic procedures was 1,037 
USD according to 2005 U.S. average Medicare 
reimbursements, which is about eight times higher 
than the screening mammography[5] and out of 
pocket charges by private clinics are as much as 
5 times higher.
Ultrasound and MR elasticity imaging
In the last decade a new modality for cancer 
diagnostics termed Elasticity Imaging (EI) has 
emerged. EI allows visualization and semi quan-
titative assessment of mechanical properties of soft 
tissue. Mechanical properties of tissues, i.e. is 
elastic modulus and viscosity, are highly sensitive 
to tissue structural changes accompanying various 
physiological and pathological processes. A change 
in Young’s modulus of tissue during the develop-
ment of a tumor could reach thousands of percent 
[30–32]. EI is based on generating a stress in the 
tissue using various static or dynamic means and 
measuring resulting strain by ultrasound or MRI 
[33–39]. The current increasing ﬂ  ow of publica-
tions from many countries all over the world on 
Elastography covers practically all key human 
organs[40–46].
Tactile imaging
Tactile Imaging (TI), an alternative version of 
Elasticity Imaging, yields a tissue elasticity map, 
similarly to other elastographic techniques. At the 94
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same time, TI, which is also called “stress 
imaging” or “mechanical imaging” [56–61], most 
closely mimics manual palpation, since the TI 
probe with a pressure sensor array mounted on its 
face acts similar to human ﬁ  ngers during clinical 
examination, slightly compressing soft tissue by 
the probe.
There are limited clinical data on diagnostic/
screening potential of breast TI. In one clinical 
study that included 110 patients with a complaint 
of a breast mass, TI demonstrated detection of 94% 
of the breast mass, while physical examination 
identiﬁ  ed only 86%[57]. The positive predictive 
value for breast cancer using TI was 94% and 78% 
for physical examination. Clinical results of 
another study for 187 cases, collected at 4 different 
clinical sites, have demonstrated that TI produces 
a reliable image formation of breast tissue abnor-
malities with increased hardness and calculation 
of lesion features[60]. Malignant breast lesions 
(histologically conﬁ  rmed) demonstrated increased 
hardness and strain hardening as well as decreased 
mobility and relative boundary length in com-
parison with benign lesions. Statistical analysis of 
the TI differentiation capability for 154 benign and 
33 malignant lesions revealed an average sensitivity 
of 89.4% and speciﬁ  city of 88.9% with a standard 
deviation of ±7.8%. The area under the receiver 
operating characteristic curve characterizing 
benign and malignant lesion discrimination was 
87.8% with the conﬁ  dence interval range from 
82.1% to 92.1%, with a significance level 
P = 0.0001.
In Table 1 we summarized recent clinical results 
on benign/malignant breast lesion differentiation 
by various elasticity imaging modalities: USE—
Ultrasound Elastography, MRE—Magnetic 
Resonance Elastography and TI. These data show 
that elasticity imaging even in its simplest and least 
sophisticated versions, like TI, has signiﬁ  cant 
Table 1. Recent clinical data on benign-malignant breast lesion differentiation by elasticity imaging.
No. Method Number of analyzed 
lesions
Sensitivity Speciﬁ  city Citation
1 USE* 52 malignant 86.5% 89.8% Itoh A, et al. 2006 [47]
59 benign
2 USE 135 total 100.0% 95.0% Zhang XF, et al. 2006 [48]
3 USE 49 malignant 91.8% 91.5% Thomas A, et al. 2006 [49]
59 benign
4 MRE* 38 malignant 95.0% 80.0% Sinkus R, et al. 2006 [50]
30 benign
5 USE 88 total 96.0% 61.0% Renger DM, et al. 2006 [51]
6 USE 43 malignant 100.0% 96.0% Barr RG, 2007 [52]
150 benign
7 USE 115 total 90.0% – Garra BS, et al. 2006 [53]
8 USE 50 malignant 99.3% 25.7% Burnside ES, et al. 2007 [54]
48 benign
9 USE 237 malignant 97.5% 48.0% Svensson WE, et al. 2007 [55]
584 benign
10 TI* 34 malignant 94.4% – Kaufman CS, et al. 2006 [57]
76 benign
11 TI 33 malignant 89.4% 88.9% Egorov V, et al. 2008 [60]
154 benign
12 SSI* 4 malignant 100.0% 100.0% Tanter M, et al. 2008 [75]
11 benign
USE*—Ultrasound Elastography, MRE*—Magnetic Resonance Elastography, TI*—Tactile Imaging,
SSI*—Supersonic Shear Imaging.95
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diagnostic potential comparable and exceeding that 
of conventional imaging techniques such as mam-
mography, MRI and ultrasound.
Biopsy
Although the most of women who undergo screen-
ing each year do not have breast cancer, about 
5%–10% of women have their mammogram inter-
preted as abnormal or inconclusive until further 
tests are done. In most instances, additional tests 
(imaging studies and/or biopsy) lead to a ﬁ  nal 
interpretation of normal breast tissue or benign 
[10]. In the United States alone, more than 1 million 
breast biopsies are performed annually and approx-
imately 80% of these ﬁ  ndings are benign[62, 63]. 
In general, the biopsy diagnostic cancer sensitivity 
varies from 91% to 100% (in average 96.6%) for 
8 clinical trials, and depends on biopsy type 
(needle, core, or surgical) and used image–guided 
technique (X-rays, ultrasound, MRI)[64]. The 
evaluations of cost effectiveness of biopsy are 
extremely diverse depending on biopsy type, used 
technique, and accepted model; it is varying from 
2,250 USD to 77,500 USD per life year saved 
[65, 66]. The cost associated with biopsy diagnostic 
procedure is in average about 1,000 USD, changing 
from 456 USD for ﬁ  ne needle aspiration biopsy to 
2,061 USD for open biopsy, according to 2005 US 
average Medicare reimbursements[5].
Cost-Effectiveness of Breast 
Cancer Screening and Diagnostic 
Methods
About 80% of the 1.6B women live in developing 
countries and 70% of breast cancer related deaths 
occur in these regions [2]. However, less than 10% 
of mammograms are conducted in these develop-
ing regions (Fig. 1) [67].
Diagnostic efﬁ  cacy is certainly an important 
measure, but affordability is another critical factor 
which needs to be considered. Based on data from 
[62] we see that the adoption of mammography is 
strongly correlated with physician income and 
consequently much more utilized in developing 
counties. As Figure 2 shows, the number of mam-
mography equipment in comparison to number of 
physicians that perform CBE is close to 20% in 
U.S.A. but less than 0.25% in India.
Table 2 presents a summary of breast cancer 
screening/diagnostic efﬁ  ciency for various tech-
niques, procedure cost and cost-effectiveness 
numbers. The cost-effectiveness data listed in the 
table are mostly taken from published sources. We 
included the range for cost-effectiveness for 
1,600 M 0.5 M 125.5 M 
Women,
25–70 y.o.
Women Cancer 
Deaths
Mammograms
Figure 1. Population of women (ﬁ  rst column), breast cancer deaths (second column) and mammography processes (third column) in devel-
oping countries (red boxes) in comparison with developed countries (grey boxes). The data are for 2005 [62].
Abbreviations: NA: North America; WE: Western Europe; JPN: Japan; LA: Latin America; EEMEA: Eastern Europe, Middle East, Africa; 
APAC: Asian Paciﬁ  c, Australia, China.96
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analyzed modalities in the Table 2 because the 
speciﬁ  c data depend on accepted population-based 
model simulating histories of women, which, as a 
rule, include breast cancer natural history, breast 
cancer detection capability of the modality, breast 
cancer treatment, and competing-cause mortality. 
Different authors often use different models for the 
cost-effectiveness evaluation.
The ‘gold standard’ in cancer diagnostics, 
biopsy, demonstrates the highest diagnostic accu-
racy close to 100%. It costs in average over 2,000 
USD for one analyzed breast lesion/location. The 
biopsy cost-effectiveness varies from 2,250 USD 
for developing countries to 77,500 USD for devel-
oped countries. The cost-effectiveness of biennial 
film mammography screening is evaluated as 
Table 2. Comparative data for breast cancer detection effectiveness and cost effectiveness.
Screening/Diagnostic 
technique
Sensitivity/Speciﬁ  city, % Procedure cost 
of ilateral exam, USD
Cost-effectiveness, USD 
per life year gained
CBE 56.5/93.7 – 522, India [7]
31,900, Japan [69]
Mammography 73.7/94.3 112* 1,846, India [7]
26,500–331,000 [5]
Ultrasound Limited, see text 70* –
MRI 87.7/92.8 1,037* 55,420–130,695 [68]
Biopsy 96.6/100.0 2,061** 2,250–77,500 [65, 66]
Elasticity Imaging 95.1
#/73.4 – –
Tactile Imaging 91.9
##/88.9 5–50*** 162***
*the U.S. average Medicare reimbursements in 2005;
**in average for one biopsy;
***projections based on a physician’s assistant performing the exam;
#averaged for 9 clinical studies;
##averaged for 2 clinical studies.
Figure 2. Relative cost of mammography equipment vs. physician adoption.97
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1,846 USD per life-year saved in India[18]. In the 
United States, the selective use of digital mam-
mography screening for women aged 40 years or 
older had costs per quality adjusted life-year 
(QALY) gained ranging from 26,500 USD for 
age-targeted digital mammography to 84,500 USD 
for age- and density-targeted digital mammogra-
phy. All-digital mammography screening was also 
more costly and no more effective than age-
targeted digital mammography. The cost per QALY 
gained for all-digital mammography relative to 
all-ﬁ  lm mammography screening was 331,000 
USD (Confidence interval, 268,000 USD to 
403,000 USD)[4].
Using cost-effectiveness of biennial CBE, 522 
USD per life-year saved in India[18], one can 
estimate the impact of TI using CBE data. Taking 
92% TI cancer sensitivity, which is 62% higher 
than CBE, may result in proportional improve-
ment in TI cost-effectiveness. Further, the TI 
examination may be performed by a nurse or 
qualified technician, rather than a physician, 
which may additionally improve the cost effec-
tiveness by a factor of two. As a result, we may 
expect TI cost effectiveness for developing coun-
tries to be equaled to 162 USD (in prices of 2001), 
which is over ten times more cost-effective than 
ﬁ  lm mammography. A rough estimate shows that 
the TI procedure could cost about 5 USD in devel-
oping countries and 50 USD in the United States. 
In addition, clinical results indicate that TI 
screening may substantially decrease the benign 
biopsy rate[60].
Conclusions
There is a tremendous worldwide need to detect 
breast cancer at its earliest stage. These needs must 
be balanced by the ability of countries to provide 
breast cancer screening technology to their 
populations. We reviewed the current available 
screening and diagnostic techniques with their 
relative cost-effectiveness ratios. In view of many 
countries with limited resources, effective yet less 
expensive modes of screening must be considered 
worldwide. Tactile imaging is one method that has 
the potential to provide cost-effective breast cancer 
screening and diagnostics.
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